Literature DB >> 21383736

Targeting the missing links for cancer therapy.

Kornelia Polyak, Judy Garber.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 21383736     DOI： 10.1038/nm0311-283

Source DB:  PubMed          Journal:  Nat Med        ISSN： 1078-8956            Impact factor:   53.440


× No keyword cloud information.
  13 in total

Review 1.  The concept of synthetic lethality in the context of anticancer therapy.

Authors:  William G Kaelin
Journal:  Nat Rev Cancer       Date:  2005-09       Impact factor: 60.716

2.  Iniparib plus chemotherapy in metastatic triple-negative breast cancer.

Authors:  Joyce O'Shaughnessy; Cynthia Osborne; John E Pippen; Mark Yoffe; Debra Patt; Christine Rocha; Ingrid Chou Koo; Barry M Sherman; Charles Bradley
Journal:  N Engl J Med       Date:  2011-01-05       Impact factor: 91.245

Review 3.  Evolution of poly(ADP-ribose) polymerase-1 (PARP-1) inhibitors. From concept to clinic.

Authors:  Dana V Ferraris
Journal:  J Med Chem       Date:  2010-06-24       Impact factor: 7.446

Review 4.  Cancer as an evolutionary and ecological process.

Authors:  Lauren M F Merlo; John W Pepper; Brian J Reid; Carlo C Maley
Journal:  Nat Rev Cancer       Date:  2006-11-16       Impact factor: 60.716

5.  Poly(ADP-ribose) polymerase (PARP-1) has a controlling role in homologous recombination.

Authors:  Niklas Schultz; Elena Lopez; Nasrollah Saleh-Gohari; Thomas Helleday
Journal:  Nucleic Acids Res       Date:  2003-09-01       Impact factor: 16.971

Review 6.  Will targeted therapy hold its promise? An evidence-based review.

Authors:  David Murdoch; Jason Sager
Journal:  Curr Opin Oncol       Date:  2008-01       Impact factor: 3.645

7.  PTEN deficiency in endometrioid endometrial adenocarcinomas predicts sensitivity to PARP inhibitors.

Authors:  Konstantin J Dedes; Daniel Wetterskog; Ana M Mendes-Pereira; Rachael Natrajan; Maryou B Lambros; Felipe C Geyer; Radost Vatcheva; Kay Savage; Alan Mackay; Christopher J Lord; Alan Ashworth; Jorge S Reis-Filho
Journal:  Sci Transl Med       Date:  2010-10-13       Impact factor: 17.956

8.  Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase.

Authors:  Helen E Bryant; Niklas Schultz; Huw D Thomas; Kayan M Parker; Dan Flower; Elena Lopez; Suzanne Kyle; Mark Meuth; Nicola J Curtin; Thomas Helleday
Journal:  Nature       Date:  2005-04-14       Impact factor: 69.504

9.  Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers.

Authors:  Peter C Fong; David S Boss; Timothy A Yap; Andrew Tutt; Peijun Wu; Marja Mergui-Roelvink; Peter Mortimer; Helen Swaisland; Alan Lau; Mark J O'Connor; Alan Ashworth; James Carmichael; Stan B Kaye; Jan H M Schellens; Johann S de Bono
Journal:  N Engl J Med       Date:  2009-06-24       Impact factor: 91.245

10.  Resistance to therapy caused by intragenic deletion in BRCA2.

Authors:  Stacey L Edwards; Rachel Brough; Christopher J Lord; Rachael Natrajan; Radost Vatcheva; Douglas A Levine; Jeff Boyd; Jorge S Reis-Filho; Alan Ashworth
Journal:  Nature       Date:  2008-02-10       Impact factor: 49.962
View more
  23 in total

Review 1.  An intermittent approach for cancer chemoprevention.

Authors:  Xiangwei Wu; Scott M Lippman
Journal:  Nat Rev Cancer       Date:  2011-11-10       Impact factor: 60.716

2.  Linking off-target kinase pharmacology to the differential cellular effects observed among PARP inhibitors.

Authors:  Albert A Antolín; Jordi Mestres
Journal:  Oncotarget       Date:  2014-05-30

3.  Merlin deficiency predicts FAK inhibitor sensitivity: a synthetic lethal relationship.

Authors:  Irina M Shapiro; Vihren N Kolev; Christian M Vidal; Yuwaraj Kadariya; Jennifer E Ring; Quentin Wright; David T Weaver; Craig Menges; Mahesh Padval; Andrea I McClatchey; Qunli Xu; Joseph R Testa; Jonathan A Pachter
Journal:  Sci Transl Med       Date:  2014-05-21       Impact factor: 17.956

Review 4.  Molecular signature of pancreatic adenocarcinoma: an insight from genotype to phenotype and challenges for targeted therapy.

Authors:  Ibrahim H Sahin; Christine A Iacobuzio-Donahue; Eileen M O'Reilly
Journal:  Expert Opin Ther Targets       Date:  2015-10-06       Impact factor: 6.902

Review 5.  Cancer biomarkers: selecting the right drug for the right patient.

Authors:  Gary J Kelloff; Caroline C Sigman
Journal:  Nat Rev Drug Discov       Date:  2012-02-10       Impact factor: 84.694

6.  The PARP inhibitors, veliparib and olaparib, are effective chemopreventive agents for delaying mammary tumor development in BRCA1-deficient mice.

Authors:  Ciric To; Eun-Hee Kim; Darlene B Royce; Charlotte R Williams; Ryan M Collins; Renee Risingsong; Michael B Sporn; Karen T Liby
Journal:  Cancer Prev Res (Phila)       Date:  2014-05-09

7.  A simple fluorescent assay for the discovery of protein-protein interaction inhibitors.

Authors:  Mona Al-Mugotir; Carol Kolar; Krysten Vance; David L Kelly; Amarnath Natarajan; Gloria E O Borgstahl
Journal:  Anal Biochem       Date:  2019-01-30       Impact factor: 3.365

Review 8.  Overcoming implementation challenges of personalized cancer therapy.

Authors:  Funda Meric-Bernstam; Gordon B Mills
Journal:  Nat Rev Clin Oncol       Date:  2012-07-31       Impact factor: 66.675

9.  NEM-Tar: A Probabilistic Graphical Model for Cancer Regulatory Network Inference and Prioritization of Potential Therapeutic Targets From Multi-Omics Data.

Authors:  Yuchen Zhang; Lina Zhu; Xin Wang
Journal:  Front Genet       Date:  2021-04-22       Impact factor: 4.599

10.  Inhibiting delta-6 desaturase activity suppresses tumor growth in mice.

Authors:  Chengwei He; Xiying Qu; Jianbo Wan; Rong Rong; Lili Huang; Chun Cai; Keyuan Zhou; Yan Gu; Steven Y Qian; Jing X Kang
Journal:  PLoS One       Date:  2012-10-24       Impact factor: 3.240
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.